Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
Astellas Pharma Global Development, Inc.
Kohei Shitara; Florian Lordick; Yung-Jue Bang; Peter Enzinger; David Ilson; Manish A Shah; Eric Van Cutsem; Rui-Hua Xu; Giuseppe Aprile; Jianming Xu; Joseph Chao; Roberto Pazo-Cid; Yoon-Koo Kang; Jianning Yang; Diarmuid Moran; Pranob Bhattacharya; Ahsan Arozullah; Jung Wook Park; Mok Oh; Jaffer A Ajani